Thiophene substituted dihydropyridines

被引:39
作者
Caignan, GA [1 ]
Metcalf, SK [1 ]
Holt, EM [1 ]
机构
[1] Oklahoma State Univ, Dept Chem, Stillwater, OK 74078 USA
关键词
dihydropyridine; calcium beta blocker; conformation;
D O I
10.1023/A:1009538107356
中图分类号
O7 [晶体学];
学科分类号
0702 ; 070205 ; 0703 ; 080501 ;
摘要
The crystal structures of 4-(2-thiophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-bis(methoxycarbonyl) (I)[a = 10.273(5) Angstrom, b = 10.428(5) Angstrom, c = 14.799(9) Angstrom, beta = 98.13(4)degrees, P2(1)/c], 4-(3-thiophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-bis(methoxycarbonyl) (II) [a = 10.636 (9) Angstrom, b = 10.372(8) Angstrom, c = 15.043(15) Angstrom, beta = 98.13(6)degrees, P2(1)/c], and 4-(2-thiophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-bis(ethoxycarbonyl) (III) [a = 26.793(16) Angstrom, b = 7.610(6) Angstrom, c = 17.612(10) Angstrom, beta = 97.61(2)degrees, C2/c] reveal patterns of hydrogen bonding pertinent to behavior of these members of the 1,4-dihydropyridine family in receptor site docking. Carbonyl groups substituted at C3 and C5 are seen in ap conformation when hydrogen bonded. Sulphur atoms of the hetero rings do not participate in hydrogen bonding. In these structures the position of the herero atom is seen to be disordered over two equivalent sites. Thus, there is no demonstrated preference for conformation of the hetero ring.
引用
收藏
页码:415 / 422
页数:8
相关论文
共 15 条
[1]  
BOULOUARD M, 1995, CHEM PHARM BULL, V43, P162
[2]  
Caignan GA, 2000, Z KRISTALLOGR, V215, P122
[3]  
JANIS RA, 1991, CALCIUM CHANNELS THE, P195
[4]  
Kappe CO, 1997, TETRAHEDRON, V53, P2803
[5]   Structure-function relationships of calcium antagonists [J].
Rojstaczer, N ;
Triggle, DJ .
BIOCHEMICAL PHARMACOLOGY, 1996, 51 (02) :141-150
[6]   CALCIUM-ENTRY BLOCKERS AND ACTIVATORS - CONFORMATIONAL AND STRUCTURAL DETERMINANTS OF DIHYDROPYRIMIDINE CALCIUM-CHANNEL MODULATORS [J].
ROVNYAK, GC ;
KIMBALL, SD ;
BEYER, B ;
CUCINOTTA, G ;
DIMARCO, JD ;
GOUGOUTAS, J ;
HEDBERG, A ;
MALLEY, M ;
MCCARTHY, JP ;
ZHANG, RA ;
MORELAND, S .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (01) :119-129
[7]   Dimethyl 2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate, diethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, and diethyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate [J].
Rowan, KR ;
Holt, EM .
ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS, 1996, 52 :1565-1570
[8]   Dibutyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, diisobutyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate and di-tert-butyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate [J].
Rowan, KR ;
Holt, EM .
ACTA CRYSTALLOGRAPHICA SECTION C-STRUCTURAL CHEMISTRY, 1996, 52 :2207-2212
[9]  
ROWAN KR, 1996, THESIS OKLAHOMA STAT
[10]  
Sheldrick G.M., 1993, PROGRAM CRYSTAL STRU